[go: up one dir, main page]

WO2004056850A3 - Mutant proteins showing increased secretion - Google Patents

Mutant proteins showing increased secretion Download PDF

Info

Publication number
WO2004056850A3
WO2004056850A3 PCT/EP2003/051050 EP0351050W WO2004056850A3 WO 2004056850 A3 WO2004056850 A3 WO 2004056850A3 EP 0351050 W EP0351050 W EP 0351050W WO 2004056850 A3 WO2004056850 A3 WO 2004056850A3
Authority
WO
WIPO (PCT)
Prior art keywords
mutant proteins
increased secretion
showing increased
relates
proteins showing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/051050
Other languages
French (fr)
Other versions
WO2004056850A2 (en
Inventor
Lothar Steidler
Sabine Neirynck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Gent, Vlaams Instituut voor Biotechnologie VIB filed Critical Universiteit Gent
Priority to AU2003303222A priority Critical patent/AU2003303222A1/en
Publication of WO2004056850A2 publication Critical patent/WO2004056850A2/en
Publication of WO2004056850A3 publication Critical patent/WO2004056850A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to proteins that carry a mutation in the amino terminal part of the mature protein, which causes an improved secretion of the mutated protein form in gram-positive bacteria, without affecting the biological activity. More particularly, it relates to a protein where a proline has been replaced in the first (10) amino acids of the mature protein. In a preferred embodiment, the invention relates to hypersecreting mutants of interleukin (6) and interleukin (10).
PCT/EP2003/051050 2002-12-19 2003-12-18 Mutant proteins showing increased secretion Ceased WO2004056850A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003303222A AU2003303222A1 (en) 2002-12-19 2003-12-18 Mutant proteins showing increased secretion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02080625 2002-12-19
EP02080625.3 2002-12-19

Publications (2)

Publication Number Publication Date
WO2004056850A2 WO2004056850A2 (en) 2004-07-08
WO2004056850A3 true WO2004056850A3 (en) 2004-09-30

Family

ID=32668874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/051050 Ceased WO2004056850A2 (en) 2002-12-19 2003-12-18 Mutant proteins showing increased secretion

Country Status (2)

Country Link
AU (1) AU2003303222A1 (en)
WO (1) WO2004056850A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc Methods of using interleukin-10 for treating diseases and disorders
EP2989240A4 (en) * 2013-04-24 2016-10-19 Armo Biosciences Inc Interleukin-10 compositions and uses thereof
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
HK1226308A1 (en) 2013-08-30 2017-09-29 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015070060A1 (en) 2013-11-11 2015-05-14 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
WO2016064817A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP7121496B2 (en) 2015-05-28 2022-08-18 アルモ・バイオサイエンシーズ・インコーポレイテッド Pegylated interleukin-10 for use in cancer therapy
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
US10858663B2 (en) 2016-09-02 2020-12-08 Intrexon Actobiotics N.V. Genetically modified bacteria stably expressing IL-10 and insulin
CN113811549A (en) 2019-02-21 2021-12-17 Xencor股份有限公司 Untargeted and targeted IL-10 FC fusion proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090551A2 (en) * 2001-05-03 2002-11-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Self-containing lactococcus strain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090551A2 (en) * 2001-05-03 2002-11-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Self-containing lactococcus strain

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BARTHELEMY I ET AL: "Production and secretion of human interleukin 6 into the periplasm of Escherichia coli: Efficient processing of N-terminal variants of hIL6 by the Escherichia coli signal peptidase", JOURNAL OF BIOTECHNOLOGY, vol. 27, no. 3, 1993, pages 307 - 316, XP002290236, ISSN: 0168-1656 *
KOHARA A ET AL: "ALTERATION OF AMINO TERMINAL RESIDUES OF MATURE HUMAN LYSOZYME AFFECTS ITS SECRETION IN YEAST AND TRANSLOCATION INTO CANINE MICROSOMAL VESICLES", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 30, 1991, pages 20363 - 20368, XP002290237, ISSN: 0021-9258 *
SHIGA YASUHIRO ET AL: "Efficient production of N-terminally truncated biologically active human interleukin-6 by Bacillus brevis", BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, vol. 64, no. 3, March 2000 (2000-03-01), pages 665 - 669, XP009034553, ISSN: 0916-8451 *
STEIDLER L ET AL: "Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 21, no. 7, July 2003 (2003-07-01), pages 785 - 789, XP002276104, ISSN: 1087-0156 *
STEIDLER L ET AL: "Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 66, no. 7, July 1998 (1998-07-01), pages 3183 - 3189, XP002105819, ISSN: 0019-9567 *
STEIDLER L: "IN SITU DELIVERY OF CYTOKINES BY GENETICALLY ENGINEERED LACTOCOCCUS LACTIS", ANTONIE VAN LEEUWENHOEK, DORDRECHT, NL, vol. 82, no. 1/2, August 2002 (2002-08-01), pages 323 - 331, XP008011638 *

Also Published As

Publication number Publication date
AU2003303222A1 (en) 2004-07-14
AU2003303222A8 (en) 2004-07-14
WO2004056850A2 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
CA2395266A1 (en) Use of acid-stable subtilisin proteases in animal feed
WO2004056850A3 (en) Mutant proteins showing increased secretion
EP1013760A3 (en) Stable bactericidal/permeabilityincreasing protein products and pharmaceutical compositions containing the same
WO2001079463A3 (en) Nucleic acids encoding polypeptides having haloperoxidase activity
CA2200563A1 (en) Calcium free subtilisin mutants
WO1999033960A3 (en) Proteases from gram positive organisms
WO1999034003A3 (en) Proteases from gram positive organisms
WO2004007695A3 (en) Lactobacilli expressing biologically active polypeptides and uses thereof
AU2002236300A1 (en) Novel protein, gene encoding the same and method of using the same
AU2003223934A1 (en) Recombinant bet. v. 1. allergen mutants, methods and process thereof
WO2000001831A3 (en) Proteases fused with variants of streptomyces subtilisin inhibitor
WO1999000407A3 (en) Improved bacillus thuringiensis toxin
AU2002349231A1 (en) Methylotrophic bacterium for the production of recombinant proteins and other products
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
AU3711597A (en) A novel galanin receptor
AU2003264535A1 (en) Tumor antigen protein and utilization thereof
AU2001240540A1 (en) Method for the manufacture of recombinant trypsin
AU8493198A (en) Increasing production of proteins in gram-positive microorganisms
WO2004060909A3 (en) Increasing production of proteins in gram-positive microorganisms
WO2002079459A3 (en) Means for inhibiting proteolytical processing of parkin
WO2003025004A3 (en) Purified bacterial polypeptides involved in nucleic acid processing
WO2004042043A3 (en) Crystal structures of bacterial ribulose-phosphate 3-epimerases
AU2001258222A1 (en) Phytase polypeptides
WO2004013167A3 (en) Purified polypeptides from enterococcus faecalis
WO2004069989A3 (en) Novel purified phosphodiesterase polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP